Background: Moyamoya disease is a relatively rare cerebrovascular occlusive disorder. Several studies have reported cerebral microbleeds (CMBs) in moyamoya disease patients using T2*-weighted imaging (T2*WI) and/or susceptibilityweighted imaging (SWI). Purpose: To investigate the incidence, distribution patterns, and influencing factors of asymptomatic CMBs in patients with moyamoya disease. Material and Methods: Phase-sensitive imaging (PSI) was used to investigate 27 consecutive moyamoya disease patients with a 3-T magnetic resonance imaging system, then a meta-analysis of 245 patients (asymptomatic moyamoya disease, n ¼ 23; ischemic moyamoya disease, n ¼ 161; hemorrhagic moyamoya disease, n ¼ 61) from four previous individual studies and our PSI study was performed. The meta-analysis was performed in accordance with the Preferred Reporting Items for Systematic reviews and Meta-Analyses (PRISMA) guidelines. Based on the clinical and radiological data, we divided the studies into different model groups to calculate the incidence of CMBs and discuss the distribution patterns of CMBs. Results: Thirty-five asymptomatic CMBs were demonstrated in 14 moyamoya disease patients (51.9%) in our PSI study. Of these, 45.7% were located in the periventricular white matter. In the meta-analysis, the pooled incidence of asymptomatic CMBs in moyamoya disease was 46% (95% confidence interval [CI], 28.2-63.8%) on SWI or PSI and 29.6% (95% CI, 17.4-41.7%) on T2*WI. Statistical analysis showed that PSI or SWI offered better detection of CMBs in moyamoya disease than T2*WI, and 3-T T2*WI offered better detection than 1.5-T T2*WI. Furthermore, hemorrhagic onset-type moyamoya disease correlated with a high incidence of asymptomatic CMBs. Conclusion: PSI or SWI can detect CMBs better than T2*WI, and 3-T T2*WI. Hemorrhagic onset-type moyamoya disease seems to correlate with a high incidence of asymptomatic CMBs. The meta-analysis indicates that asymptomatic CMBs may be an important factor for hemorrhagic stroke risk. Long-term evaluation of CMBs using PSI or SWI may contribute to the management of moyamoya disease.
Introduction
Moyamoya disease is a relatively rare cerebrovascular occlusive disorder most often found among the Japanese, although cases have also been described in other countries (1) . This pathology is characterized by progressive stenosis and, ultimately, occlusion of the terminal portion of the internal carotid artery, proximal middle cerebral artery, and anterior cerebral artery. Consequently, parenchymal, leptomeningeal, and/or transdural collateral vessels develop around the blocked vessels to compensate for these blockages, but the collateral vessels are small, weak, and prone to hemorrhage, aneurysm, and thrombosis (2) (3) (4) . Moyamoya disease primarily affects children and adults in their 30s and 40s (5) . Adults more often suffer from hemorrhages, whereas children experience ischemic accidents (6, 7) . Although the cause of the disease remains unclear, some researchers believe asymptomatic cerebral microbleeds (CMBs) may be associated with a risk of hemorrhage in moyamoya disease patients (8, 9) . These hemorrhagic foci are most commonly located in the periventricular region, basal ganglia, and thalamus, but intraventricular bleeding alone or in combination with intracerebral hemorrhage also occurs. Subarachnoid hemorrhage is rare, but may be seen over the cerebral convexities (10) . Such events are assumed to result from the collapse of fragile moyamoya vessels by hemodynamic loading and rupture of the peripheral aneurysms that often form on moyamoya vessels (11) . Several studies have reported CMBs in moyamoya disease patients using T2*-weighted imaging (T2*WI) and/or susceptibility-weighted imaging (SWI). Such investigations have shown the incidence of CMBs detected by T2*WI in adult patients with moyamoya disease was higher than that in healthy individuals, indicating that multiple CMBs are predictive of subsequent symptomatic hemorrhage in these patients (8, 9, 12) .
Certainly, SWI is more sensitive for detecting CMBs than T2*WI, and SWI on 3-T magnetic resonance imaging (MRI) offers better detection of CMBs than that at 1.5 T (13, 14) . However, only a few studies have reported CMBs in moyamoya disease patients using SWI, particularly with 3-T MRI (15) . Meanwhile, different risk rates of CMBs in moyamoya disease patients have been shown in several papers (12, 15) . To further clarify the situation in moyamoya disease patients, we investigated the incidence, distribution patterns, and influencing factors of asymptomatic CMBs using phase-sensitive imaging (PSI) on the basis of principles similar to those of SWI. For this purpose, we also performed a pooled meta-analysis of all controlled studies identified in the literature. From 2007 to April 2013, a total of 27 consecutive  patients who had been diagnosed with moyamoya disease based on angiographic findings (19 girls/women, 8 boys/men; age range, 7-71 years; mean AE standard deviation, 34.3 AE 20.4 years) were studied by PSI using 3-T MRI. Moyamoya disease was diagnosed in 12 pediatric patients (<15 years old when symptoms of moyamoya disease were identified) and in 15 adult patients. Mean ages of onset were 7.8 and 45 years, respectively, in those two groups. Duration from disease onset to initial PSI was in the range of 0-401 months (mean, 75.5 AE 99.3 months; median, 35 months).
Material and Methods

Patients in the PSI study
The onset symptoms and signs were transient ischemic attacks (TIA), infarction, or cerebral hemorrhage including subarachnoidal hemorrhage. Therefore, based on initial symptoms and radiological findings, we divided these patients into two types: ischemic onset-type moyamoya disease (n ¼ 17); and hemorrhagic onset-type moyamoya disease (n ¼ 10). Mean ages at initial PSI were 28.4 AE 18.8 and 44.2 AE 19 years, respectively. Among these patients, hypertension was diagnosed in 13, hyperlipidemia in six, diabetes mellitus in five, cerebral aneurysm in one, and arteriovenous malformation in one. Ten patients had undergone surgical treatment before the initial PSI study. Thirteen patients (10 girls/women, 3 boys/men) were followed. Duration of follow-up was in the range of 10-57 months (mean, 38 AE 12.1 months; median, 36 months). After the initial PSI study, two of the 13 patients underwent bypass surgery during follow-up. The clinical features and radiological findings of subjects are summarized in Table 1 .
The study was approved by the local institutional review board with a waiver for informed consent.
MR technique
Initial and follow-up PSI studies were undertaken on the same 3-T MRI unit (Signa Excite HD; GE Healthcare, Milwaukee, WI, USA) using an eight-channel phased-array coil (USA Instruments; Aurora, OH, USA). Axial T2-weighted fast spin-echo images were also obtained with the following imaging parameters: repetition time (TR), 4000 ms; echo time (TE), 95 ms; matrix, 512 Â 320; field of view (FOV), 21 cm; section thickness, 5 mm; intersection gap, 1.5 mm. PSI on the basis of principles similar to those of SWI was performed with a three-dimensional spoiled gradientrecalled sequence with flow compensation, using the following imaging parameters: TR, 45 ms; TE, 30 ms; flip angle, 20 ; FOV, 21 cm; matrix, 512 Â 192; section thickness, 1.5 mm; acquisition time, 7 min 40-50 s. All images were obtained in the axial plane. Next, we postprocessed the phase-sensitive images using a high-pass filter and then converted the images into negative-phase masks that were multiplied four times into the corresponding magnitude images using research software (PSI Recon; GE Yokogawa Medical Systems, Tokyo, Japan). Last, we used a minimal-intensity projection to display the processed data and contiguous 10.5 mmthick sections with 7 mm overlap in the transverse plane (Advantage workstation version 4.1; GE Healthcare) (16) .
Image reading
Asymptomatic CMBs were described as small, rounded, or circular foci appearing in the hypointense area in the brain parenchyma on T2*WI and SWI (17, 18) . According to the microbleed anatomical rating scale (18), we classified CMBs into deep (including the basal ganglia, thalamus, internal capsule, external capsule, corpus callosum, and deep and periventricular white matter), lobar (including cortex and subcortical white matter), and infratentorial (including the brainstem and cerebellum) categories. The location of CMBs and clinical parameters were then statistically evaluated. The 2 test (Fisher's exact test) was used to assess relationships at a probability level of P < 0.05. In addition, to avoid potential surveillance bias, all images were independently interpreted by two neuroradiologists who were aware of the neurological condition of the patient. After that, scans of subjects rated positive for CMBs were compared side-by-side to assess the final consensual number and location of CMBs in each scan.
Meta-analysis study
Our meta-analysis was performed in accordance with the Preferred Reporting Items for Systematic reviews and Meta-Analyses (PRISMA) guidelines (19) . Using the terms ''moyamoya disease'', ''microbleed'', and ''SWI'' or ''T2*WI'', a PubMed search was performed through to 30 April 2013. No publication date or publication status restrictions were imposed. We extracted epidemiological data including study method, patient age, sex, moyamoya disease pattern, the presence or absence of CMBs, CMB locations, and the number of CMBs. Based on the clinical and radiological data, we divided the studies into different model groups to calculate the incidence of CMBs by performing general variance-based method for correlation coefficients, then used a fixed-effects model (Binary and Continuous study) to calculate the pooled relative risk in moyamoya disease patients with versus without CMBs. Last, we assessed heterogeneity using 2 statistics and through visual inspection of the forest plot.
Meta-analysis was performed using StatsDirect statistical software (version 2.7.9; StatsDirect Ltd., Altrincham, Cheshire, UK). Hazard ratios were extracted for each risk factor. In all statistical analyses, a P value <0.05 was used as the level of significance.
Results
CMBs in the PSI study
Among the 27 patients enrolled in this study, asymptomatic CMBs were found in 14 patients (51.9%; 10 girls/women, 4 boys/men) in the initial PSI study; that is, in six (35.3%) of 17 patients with ischemic onset-type moyamoya disease and eight (80%) of 10 patients with hemorrhagic onset-type moyamoya disease. In six of the 12 (50%) pediatric-onset patients with moyamoya disease and in eight of the 15 (53.3%) adult-onset patients with moyamoya disease asymptomatic CMBs were found. The prevalence of asymptomatic CMBs is summarized in Table 2 . Among these 14 patients with asymptomatic CMBs, nine had one asymptomatic CMB, two had two, and three had more than two CMBs. The total number of asymptomatic CMBs was 35. These CMBs were most prevalent in deep regions (21 of 35, 60%), followed by the lobar region (13 of 35, 37%) and infratentorial regions (1 of 35, 3%). Among these, 16 CMBs (45.7%) were located in the periventricular white matter ( Fig. 1) . Although women tended to be more often affected than men (19 vs. 8) and adultonset patients tended to be more affected than pediatric-onset patients (15 vs. 12), the incidence of asymptomatic CMBs did not differ significantly among these groups in our PSI study (P ¼ 0.3, 0.29, respectively). However, hemorrhagic onset-type (14) moyamoya disease showed a higher incidence of asymptomatic CMBs than ischemic onset-type moyamoya disease (P ¼ 0.027). During the follow-up period, PSI did not detect any new microbleeds in any moyamoya disease patients, with the exception of one man. This patient was a 71year-old ischemic onset-type moyamoya disease patient. On initial PSI, multiple CMBs were seen in left periventricular region, the corpus callosum, right parietal lobe, right occipital lobe, and left temporal stem. Four years later, a new silent CMB was found in the left putamen on follow-up imaging (Fig. 2) .
CMBs in the meta-analysis
Excluding two overlapping publications, four studies satisfied our inclusion criteria (12, 15, 20, 21) . The total of 245 patients in these studies (23 asymptomatic moyamoya disease, 161 ischemic onset-type moyamoya disease, 61 hemorrhagic onset-type moyamoya disease) were pooled in the meta-analysis, of whom 78.2% (95% CI, 73.3-83.2%) were women. Mean age at presentation was 38 AE 15.6 years (95% CI, 7.4-68.6 years). Demographic data are provided in Table 3 .
According to the methods, all patients were divided into 1.5-T T2*WI versus 3-T T2*WI model groups and T2*WI versus SWI model groups. The pooled incidences of asymptomatic CMBs on 1.5-T T2*WI and 3-T T2*WI were 20.1% (95% CI, 1.6-38.6%) and 36.7% (95% CI, 20.6-52.8%). The overall CMB rate on T2*WI was 29.6% (95% CI, 17.4-41.7%). However, the pooled incidence of asymptomatic CMBs for SWI in the study by Mori et al. and our PSI study was 46% (95% CI, 28.2-63.8%). Statistical analysis showed the rate was significantly higher on SWI or PSI compared to T2*WI (P ¼ 0.006), and with 3-T T2*WI compared to 1.5-T T2*WI (P ¼ 0.004). Furthermore, asymptomatic CMBs were most prevalent in deep regions such as periventricular white matter and basal ganglia. In particular, periventricular white matter was most frequently involved (49.7% [95% CI, 28.7-70.7%]). Meanwhile, we found that the incidence of asymptomatic CMBs was higher in hemorrhagic onset-type moyamoya disease than in non-hemorrhagic onset-type moyamoya disease. The pooled relative risk was 1.998 (95% CI, 1.364-2.924; P ¼ 0.0004) ( Fig. 3 ).
Discussion
To the best of our knowledge, the present study represents the first meta-analysis to examine the risk rate for CMBs in moyamoya disease patients. Recent studies have shown that CMBs are more sensitively detected by SWI than by T2*WI (13, 14) . Assessing 245 moyamoya disease patients, we could also confirm that SWI or PSI was more sensitive than T2*WI for detection of CMBs in moyamoya disease. The pooled incidence of asymptomatic CMBs in moyamoya disease patients was about 46% on SWI and PSI, and 29.6% on T2*WI. These rates are significantly higher than that for healthy individuals, which is believed to range between 3.1% and 9.8% (8, 9, 21) . As the incidences of CMBs with cerebral amyloid angiopathy and hypertension are 63-73% and 56%, respectively (22) (23) (24) (25) (26) (27) , the incidence of CMBs in moyamoya disease was lower than those in cerebral amyloid angiopathy or hypertension.
Concerning location, hypertensive CBMs are common in deep structures such as the basal ganglia and thalamus, and cerebral amyloid angiopathy is a common cause of spontaneous lobar hemorrhage in the elderly (27) , while CMBs in moyamoya disease patients are located mainly in the periventricular white matter. We have shown that 49.7% (95% CI, 28.7-70.7%) of CMBs were located in periventricular white matter. In particular, as reported by Kikuta et al., about 71.2% and 70% of CMBs were reported in the periventricular white matter in their two recent studies (9, 20) . The question of why these asymptomatic CMBs in moyamoya disease were usually found in periventricular white matter is important. Moyamoya vessels are formed by the development and dilatation of branching of the anterior choroidal and posterior communicating arteries that frequently supply the basal ganglia, thalamus, and periventricular areas, which are the most common sites of bleeding in moyamoya disease (28) . The precise pathophysiology that leads to hemorrhage in moyamoya disease is still not fully understood, but major underlying features that have been postulated include development of microaneurysms on dilated perforating arteries, especially in the periventricular region, and fibroid necrosis of the arterial wall in the basal ganglia (29) . A study of 107 moyamoya disease patients showed that abnormal dilatation and branching of the anterior choroidal and posterior communicating arteries yielded 86% specificity and 84% sensitivity in predicting hemorrhagic events (30) . CMBs in moyamoya disease thus may well be prone to occurring in the periventricular region. CMBs could be found in hemorrhagic onset-type, ischemic onset-type, or asymptomatic moyamoya disease, pediatric-or adult-onset moyamoya disease, and male or female patients. Most pediatric-onset moyamoya disease patients develop transient ischemic attack or cerebral infarction, whereas about half of adult-onset moyamoya disease patients develop intracranial bleeding (6, 7) . Our study confirmed these points. Our analysis found also a higher incidence of asymptomatic CMBs in hemorrhagic onset-type moyamoya disease than in ischemic onset-type moyamoya disease. Some studies have indicated that angiographic stage in moyamoya disease advances with age (31) . Reaching the next angiographic stage can take as long as 10 years (2) . When the disease process affects these normally small vessels by greatly increasing demand and promoting maximal dilation, the risk of hemorrhage is greatly increased (28) . Thus, during long-term follow-up, moyamoya stage will worsen and the incidence of asymptomatic CMBs in moyamoya disease will increase. With the exception of one new CMB in a male patient, we did not detect any new CMBs during the relatively short follow-up period (mean, 38 months) in our PSI study, but four of 17 moyamoya disease patients with CMBs developed hemorrhagic stroke during follow-up in the study by Kuroda et al. (21) . Given the fact that adult patients suffering from moyamoya disease for longer periods have a much higher rate of hemorrhagic presentation, hemorrhagic type-onset moyamoya disease shows a higher incidence of asymptomatic CMBs than the ischemic onset-type moyamoya disease frequently observed in children.
Some research has shown the mortality rate for initial intracranial hemorrhage in moyamoya disease is 6.8-17.9%, rising to 28.6-66.7% after rebleeding (32, 33) . We therefore have to follow moyamoya disease patients to evaluate new hemorrhage. A prospective study of moyamoya disease patients imaged by MRI identified the presence of multiple CMBs as an independent risk factor for subsequent hemorrhage, with symptomatic hemorrhage tending to occur at sites of previously identified CMBs (21) . The same study also found that the multiple CMBs group showed a higher likelihood of subsequent hemorrhage compared to either the non-CMB or single-CMB groups (9) . CMBs were therefore considered as a general marker of various types of bleeding-prone cerebral angiopathy and a general marker of microvascular vulnerability. Long-term evaluation of CMBs by SWI or PSI should thus contribute to the management of moyamoya disease.
This systematic review has several limitations that must be considered when interpreting the results. First, moyamoya disease is rare even in Japan (34) .
Despite our extensive search of the literature, we found only four articles that met our inclusion criteria and the number of patients in most regions was small, leading to wide CIs. Second, follow-up periods from initial PSI were too short to evaluate new CMBs. We were thus unable to accurately determine the rebleeding rate.
In conclusion, PSI or SWI can detect CMBs better than T2*WI, and 3-T T2*WI. Hemorrhagic onset-type moyamoya disease appears to correlate with a high incidence of asymptomatic CMBs. The meta-analysis indicates that asymptomatic CMBs may be an important factor for hemorrhagic stroke risk. Long-term evaluation of CMBs using PSI should contribute to the management of moyamoya disease.
